Shareholders will meet on Oct. 26 to vote on a proposed $440 million asset sale and whether to keep the fund going under Merck Mercuriadis' advisory.
Shareholders will meet on Oct. 26 to vote on a proposed $440 million asset sale and whether to keep the fund going under Merck Mercuriadis' advisory.